Background Serum C-reactive protein (CRP) is a biomarker of an acute inflammatory
response and has been successfully used as a prognostic predictor for several …

Background Few biomarkers can predict the efficiency of PD-1 blockade in patients with
hepatocellular carcinoma (HCC). This study aimed to investigate the prognostic role of AFP …

Simple Summary The use of anti-programmed cell-death protein (ligand)-1 (PD-[L] 1) is now
a standard of care for treating hepatocellular carcinoma (HCC). However, the treatment only …

Background Inflammatory response is related to cancer progression and patient survival.
However, the value in predicting survival in hepatocellular carcinoma (HCC) patients who …

Purpose At present, there are no validated biomarkers that can predict whether patients with
advanced hepatocellular carcinoma (aHCC) are likely to benefit from anti-PD-1 therapy. We …

Background C-reactive protein (CRP) is a widely used marker of systemic inflammation and
predicts poor clinical outcomes in patients with hepatocellular carcinoma (HCC); however …

Background Precise evaluation of the efficacy of immunotherapy is critical in the effective
management and treatment of advanced hepatocellular carcinoma (HCC). Therefore, the …

Purpose. To investigate the prognostic value of blood markers in patients with hepatitis B
virus (HBV)‐induced hepatocellular carcinoma (HCC) treated with PD‐1 inhibitors. Patients …

Background There are no validated biomarkers that can predict the clinical benefit of
immune checkpoint blockers against the programmed cell death protein 1 (PD‐1) treatments …

Immune checkpoint blockade has demonstrated remarkable efficacy in hepatocellular
carcinoma (HCC) but is also commonly accompanied by immune‐related adverse events …